Lymphoma Research Foundation: U.S. Food & Drug Administration Approves Tafasitamab-cxix (MONJUVI) for Diffuse Large B-Cell Lymphoma
August 04, 2020
August 04, 2020
NEW YORK, Aug. 4 -- The Lymphoma Research Foundation issued the following statement by CEO Meghan Gutierrez:
* * *
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low g . . .
* * *
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low g . . .